Skip to main content

prmt5 inhibitor azd3470

Generic: PRMT5 Inhibitor AZD3470

prmt5 inhibitor azd3470: 2 clinical trials tracked.

prmt5 inhibitor azd3470 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about prmt5 inhibitor azd3470, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors
Clinical Trial Registry Records (2)

A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies

NCT06137144Registry updated 2026-09-14·Phase 1/Phase 2·AZN
Recruiting

Primary endpoint: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

InterventionalRandomizedopen161 targetStarted 2024-01Completion 2029-0539 sites · Australia, Brazil, China, France…AstraZeneca

PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced/Metastatic Solid Tumors That Are MTAP Deficient

NCT06130553Registry updated 2026-07-13·Phase 1/Phase 2·AZN
Recruiting

Primary endpoint: All Modules: Incidence of adverse events (AEs) and serious adverse events (SAEs). To determine the RP2D of AZD3470 as monotherapy and in combination with anticancer agents

Interventionalopen334 targetStarted 2024-01Completion 2028-1221 sites · Australia, China, France, Japan…AstraZeneca